February 2021 - Volume 44 - Issue 2 - Contributor Index

Alphabetical Search
F
I
J
Q
U
X

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

van Breeschoten, Jesper; Wouters, Michel W.J.M; de Wreede, Liesbeth C.; More

American Journal of Clinical Oncology. 44(2):82-89, February 2021.

Author:
Akce, Mehmet MD

Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody

Akce, Mehmet; Liu, Yuan; Zakka, Katerina; More

American Journal of Clinical Oncology. 44(2):74-81, February 2021.

Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody

Akce, Mehmet; Liu, Yuan; Zakka, Katerina; More

American Journal of Clinical Oncology. 44(2):74-81, February 2021.

Author:
Baekey, John MA

Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial

Elinzano, Heinrich; Toms, Steven; Robison, Jordan; More

American Journal of Clinical Oncology. 44(2):49-52, February 2021.

Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody

Akce, Mehmet; Liu, Yuan; Zakka, Katerina; More

American Journal of Clinical Oncology. 44(2):74-81, February 2021.

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

van Breeschoten, Jesper; Wouters, Michel W.J.M; de Wreede, Liesbeth C.; More

American Journal of Clinical Oncology. 44(2):82-89, February 2021.

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

van Breeschoten, Jesper; Wouters, Michel W.J.M; de Wreede, Liesbeth C.; More

American Journal of Clinical Oncology. 44(2):82-89, February 2021.

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

van Breeschoten, Jesper; Wouters, Michel W.J.M; de Wreede, Liesbeth C.; More

American Journal of Clinical Oncology. 44(2):82-89, February 2021.

Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial

Elinzano, Heinrich; Toms, Steven; Robison, Jordan; More

American Journal of Clinical Oncology. 44(2):49-52, February 2021.

Author:
Cielo, Deus MD

Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial

Elinzano, Heinrich; Toms, Steven; Robison, Jordan; More

American Journal of Clinical Oncology. 44(2):49-52, February 2021.

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

van Breeschoten, Jesper; Wouters, Michel W.J.M; de Wreede, Liesbeth C.; More

American Journal of Clinical Oncology. 44(2):82-89, February 2021.

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

van Breeschoten, Jesper; Wouters, Michel W.J.M; de Wreede, Liesbeth C.; More

American Journal of Clinical Oncology. 44(2):82-89, February 2021.

Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial

Elinzano, Heinrich; Toms, Steven; Robison, Jordan; More

American Journal of Clinical Oncology. 44(2):49-52, February 2021.

Impact of p53, HIF1a, Ki-67, CA-9, and GLUT1 Expression on Treatment Outcomes in Locally Advanced Cervical Cancer Patients Treated With Definitive Chemoradiation Therapy

Gaber, Germaine; El Achy, Samar; Khedr, Gehan A.; More

American Journal of Clinical Oncology. 44(2):58-67, February 2021.

Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial

Elinzano, Heinrich; Toms, Steven; Robison, Jordan; More

American Journal of Clinical Oncology. 44(2):49-52, February 2021.

Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody

Akce, Mehmet; Liu, Yuan; Zakka, Katerina; More

American Journal of Clinical Oncology. 44(2):74-81, February 2021.

Impact of p53, HIF1a, Ki-67, CA-9, and GLUT1 Expression on Treatment Outcomes in Locally Advanced Cervical Cancer Patients Treated With Definitive Chemoradiation Therapy

Gaber, Germaine; El Achy, Samar; Khedr, Gehan A.; More

American Journal of Clinical Oncology. 44(2):58-67, February 2021.

Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody

Akce, Mehmet; Liu, Yuan; Zakka, Katerina; More

American Journal of Clinical Oncology. 44(2):74-81, February 2021.

Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial

Elinzano, Heinrich; Toms, Steven; Robison, Jordan; More

American Journal of Clinical Oncology. 44(2):49-52, February 2021.

Impact of p53, HIF1a, Ki-67, CA-9, and GLUT1 Expression on Treatment Outcomes in Locally Advanced Cervical Cancer Patients Treated With Definitive Chemoradiation Therapy

Gaber, Germaine; El Achy, Samar; Khedr, Gehan A.; More

American Journal of Clinical Oncology. 44(2):58-67, February 2021.

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

van Breeschoten, Jesper; Wouters, Michel W.J.M; de Wreede, Liesbeth C.; More

American Journal of Clinical Oncology. 44(2):82-89, February 2021.

Impact of p53, HIF1a, Ki-67, CA-9, and GLUT1 Expression on Treatment Outcomes in Locally Advanced Cervical Cancer Patients Treated With Definitive Chemoradiation Therapy

Gaber, Germaine; El Achy, Samar; Khedr, Gehan A.; More

American Journal of Clinical Oncology. 44(2):58-67, February 2021.

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

van Breeschoten, Jesper; Wouters, Michel W.J.M; de Wreede, Liesbeth C.; More

American Journal of Clinical Oncology. 44(2):82-89, February 2021.

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

van Breeschoten, Jesper; Wouters, Michel W.J.M; de Wreede, Liesbeth C.; More

American Journal of Clinical Oncology. 44(2):82-89, February 2021.

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

van Breeschoten, Jesper; Wouters, Michel W.J.M; de Wreede, Liesbeth C.; More

American Journal of Clinical Oncology. 44(2):82-89, February 2021.

Impact of p53, HIF1a, Ki-67, CA-9, and GLUT1 Expression on Treatment Outcomes in Locally Advanced Cervical Cancer Patients Treated With Definitive Chemoradiation Therapy

Gaber, Germaine; El Achy, Samar; Khedr, Gehan A.; More

American Journal of Clinical Oncology. 44(2):58-67, February 2021.

Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody

Akce, Mehmet; Liu, Yuan; Zakka, Katerina; More

American Journal of Clinical Oncology. 44(2):74-81, February 2021.

Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial

Elinzano, Heinrich; Toms, Steven; Robison, Jordan; More

American Journal of Clinical Oncology. 44(2):49-52, February 2021.

Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody

Akce, Mehmet; Liu, Yuan; Zakka, Katerina; More

American Journal of Clinical Oncology. 44(2):74-81, February 2021.

Author:
Mohler, Alex MD

Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial

Elinzano, Heinrich; Toms, Steven; Robison, Jordan; More

American Journal of Clinical Oncology. 44(2):49-52, February 2021.

Impact of p53, HIF1a, Ki-67, CA-9, and GLUT1 Expression on Treatment Outcomes in Locally Advanced Cervical Cancer Patients Treated With Definitive Chemoradiation Therapy

Gaber, Germaine; El Achy, Samar; Khedr, Gehan A.; More

American Journal of Clinical Oncology. 44(2):58-67, February 2021.

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

van Breeschoten, Jesper; Wouters, Michel W.J.M; de Wreede, Liesbeth C.; More

American Journal of Clinical Oncology. 44(2):82-89, February 2021.

Impact of p53, HIF1a, Ki-67, CA-9, and GLUT1 Expression on Treatment Outcomes in Locally Advanced Cervical Cancer Patients Treated With Definitive Chemoradiation Therapy

Gaber, Germaine; El Achy, Samar; Khedr, Gehan A.; More

American Journal of Clinical Oncology. 44(2):58-67, February 2021.

Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial

Elinzano, Heinrich; Toms, Steven; Robison, Jordan; More

American Journal of Clinical Oncology. 44(2):49-52, February 2021.

Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial

Elinzano, Heinrich; Toms, Steven; Robison, Jordan; More

American Journal of Clinical Oncology. 44(2):49-52, February 2021.

Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody

Akce, Mehmet; Liu, Yuan; Zakka, Katerina; More

American Journal of Clinical Oncology. 44(2):74-81, February 2021.

Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody

Akce, Mehmet; Liu, Yuan; Zakka, Katerina; More

American Journal of Clinical Oncology. 44(2):74-81, February 2021.

Impact of p53, HIF1a, Ki-67, CA-9, and GLUT1 Expression on Treatment Outcomes in Locally Advanced Cervical Cancer Patients Treated With Definitive Chemoradiation Therapy

Gaber, Germaine; El Achy, Samar; Khedr, Gehan A.; More

American Journal of Clinical Oncology. 44(2):58-67, February 2021.

Impact of p53, HIF1a, Ki-67, CA-9, and GLUT1 Expression on Treatment Outcomes in Locally Advanced Cervical Cancer Patients Treated With Definitive Chemoradiation Therapy

Gaber, Germaine; El Achy, Samar; Khedr, Gehan A.; More

American Journal of Clinical Oncology. 44(2):58-67, February 2021.

Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial

Elinzano, Heinrich; Toms, Steven; Robison, Jordan; More

American Journal of Clinical Oncology. 44(2):49-52, February 2021.

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

van Breeschoten, Jesper; Wouters, Michel W.J.M; de Wreede, Liesbeth C.; More

American Journal of Clinical Oncology. 44(2):82-89, February 2021.

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

van Breeschoten, Jesper; Wouters, Michel W.J.M; de Wreede, Liesbeth C.; More

American Journal of Clinical Oncology. 44(2):82-89, February 2021.

Author:
Toms, Steven MD

Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial

Elinzano, Heinrich; Toms, Steven; Robison, Jordan; More

American Journal of Clinical Oncology. 44(2):49-52, February 2021.

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

van Breeschoten, Jesper; Wouters, Michel W.J.M; de Wreede, Liesbeth C.; More

American Journal of Clinical Oncology. 44(2):82-89, February 2021.

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

van Breeschoten, Jesper; Wouters, Michel W.J.M; de Wreede, Liesbeth C.; More

American Journal of Clinical Oncology. 44(2):82-89, February 2021.

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

van Breeschoten, Jesper; Wouters, Michel W.J.M; de Wreede, Liesbeth C.; More

American Journal of Clinical Oncology. 44(2):82-89, February 2021.

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

van Breeschoten, Jesper; Wouters, Michel W.J.M; de Wreede, Liesbeth C.; More

American Journal of Clinical Oncology. 44(2):82-89, February 2021.

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

van Breeschoten, Jesper; Wouters, Michel W.J.M; de Wreede, Liesbeth C.; More

American Journal of Clinical Oncology. 44(2):82-89, February 2021.

Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial

Elinzano, Heinrich; Toms, Steven; Robison, Jordan; More

American Journal of Clinical Oncology. 44(2):49-52, February 2021.

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

van Breeschoten, Jesper; Wouters, Michel W.J.M; de Wreede, Liesbeth C.; More

American Journal of Clinical Oncology. 44(2):82-89, February 2021.

Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody

Akce, Mehmet; Liu, Yuan; Zakka, Katerina; More

American Journal of Clinical Oncology. 44(2):74-81, February 2021.

Impact of p53, HIF1a, Ki-67, CA-9, and GLUT1 Expression on Treatment Outcomes in Locally Advanced Cervical Cancer Patients Treated With Definitive Chemoradiation Therapy

Gaber, Germaine; El Achy, Samar; Khedr, Gehan A.; More

American Journal of Clinical Oncology. 44(2):58-67, February 2021.

Impact of p53, HIF1a, Ki-67, CA-9, and GLUT1 Expression on Treatment Outcomes in Locally Advanced Cervical Cancer Patients Treated With Definitive Chemoradiation Therapy

Gaber, Germaine; El Achy, Samar; Khedr, Gehan A.; More

American Journal of Clinical Oncology. 44(2):58-67, February 2021.

Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial

Elinzano, Heinrich; Toms, Steven; Robison, Jordan; More

American Journal of Clinical Oncology. 44(2):49-52, February 2021.

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

van Breeschoten, Jesper; Wouters, Michel W.J.M; de Wreede, Liesbeth C.; More

American Journal of Clinical Oncology. 44(2):82-89, February 2021.

Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody

Akce, Mehmet; Liu, Yuan; Zakka, Katerina; More

American Journal of Clinical Oncology. 44(2):74-81, February 2021.

Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody

Akce, Mehmet; Liu, Yuan; Zakka, Katerina; More

American Journal of Clinical Oncology. 44(2):74-81, February 2021.

Show: